bioAffinity Technologies, Inc. Investment Guide

Thinking about buying into bioAffinity Technologies? It is exciting to look at new biotech companies, but you need to cut through the "science-speak." Here is the breakdown in plain English.

1. What does this company actually do?

BioAffinity is a diagnostic company. Their main product is CyPath® Lung.

Doctors usually perform invasive biopsies to confirm lung cancer. BioAffinity’s test is non-invasive: a patient provides a sputum sample by coughing into a cup. The company’s technology uses a special dye that makes cancer cells "light up" under a microscope. This helps doctors decide if a patient needs more testing or can safely wait. The company uses its subsidiary, Precision Pathology Services, to process these tests in their lab.

2. How do they make money and are they growing?

They are in the early stages of commercialization. While they generated no revenue from sales before 2022, they reported approximately $2.5 million in 2023 and $9.4 million in 2024.

The Reality Check: That revenue jump looks impressive, but the company is not yet profitable. They spend significantly more on research and operations than they earn. You are not buying a company with steady profits; you are buying into the potential for future growth. The company relies entirely on raising more money to survive. They have recurring losses and a large accumulated deficit. They have stated that their ability to stay in business depends on finding more funding; if they cannot raise enough cash, they may have to shut down.

3. What’s happening with this stock offering?

The company is raising money by selling shares and "warrants." A warrant is essentially a coupon that lets you buy more shares later at a set price.

This deal is complex:

• The Warrants: For every share you buy, you get a "May 2025 Warrant" to purchase 1.5 additional shares.
• The Catch: These warrants have "anti-dilution" features. If the company sells shares later at a lower price, the number of shares you can buy with your warrant could grow significantly. This could lead to more shares being issued, which reduces your ownership percentage in the company. Additionally, the price to use these warrants might drop, which further impacts the value of your existing shares.

4. What are the main risks I should worry about?

Biotech is a high-risk sector. Keep these points in mind:

• Financial Survival: The company admits it needs more cash to stay in business. Their history of losses creates doubt about their ability to keep operating without constant outside funding.
• Regulatory Hurdles: They must navigate a complex FDA landscape. CyPath® Lung is currently sold as a Laboratory Developed Test (LDT). If the FDA changes its rules, the company might face a much more expensive approval process. If they fail these standards, or if their tests are found to be ineffective, the business could collapse.
• Competition: The diagnostic space is crowded with giants like Exact Sciences and Guardant Health. BioAffinity is a small player with limited resources to compete against these established firms.
• Global Uncertainty: The company notes that inflation, interest rates, and geopolitical tensions could disrupt their supply chain, increase costs, and make it harder to raise money.

5. Who's running the company?

Maria Zannes serves as President and CEO. She has a background in law and business and has led the company’s transition from a research lab to a commercial business.

6. Where does it trade?

They trade on the Nasdaq under the ticker symbol BIAF.

Final Thought for Investors

Before you invest, ask yourself: Am I comfortable with a company that is currently losing money and relies on constant fundraising to keep the lights on?

If you are interested, don't stop here. Go to the SEC EDGAR website and search for "BIAF." Read the "Risk Factors" section of their latest prospectus—it is the most honest document the company is legally required to write.

Disclaimer: I am an AI, not a financial advisor. IPOs and secondary offerings are inherently risky. Never rely on marketing materials—only the official SEC filings count.